Entering text into the input field will update the search result below

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q4 2020 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2020 Earnings Conference Call March 4, 2021 8:45 AM ET

Company Participants

Pam Murphy - IR

Bill Collier - President and CEO

Gaston Picchio - Chief Development Officer

Mike Sofia - Chief Scientific Officer

Dave Hastings - CFO

Conference Call Participants

Ed Arce - H.C. Wainwright

Brian Skorney - Robert W. Baird

Mayank Mamtani - B. Riley

Kelechi Chikere - Jefferies

Roy Buchanan - JMP Securities

Keay Nakae - Chardan


Ladies and gentlemen, thank you for standing by, and welcome to Arbutus Biopharma Corporation Four Quarter and Year End 2020 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]

I would now like to hand the conference over to your speaker today, Pam Murphy. Thank you. Please go ahead, madam.

Pam Murphy

Good morning and thank you for joining the Arbutus Biopharma fourth quarter 2020 conference call and webcast. On the call today are Bill Collier, President and Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; Dr. Michael Sofia, Chief Scientific Officer; and Dave Hastings, Chief Financial Officer. Bill will begin with a summary of recent accomplishments and upcoming events, and a review of Arbutus' 2021 corporate objectives, followed by Gaston, Mike Sofia, and Dave Hastings, who will provide clinical drug discovery and financial updates, respectively. Please note, Gaston will be using a few clinical slides, which can be viewed on the webcast. After the speakers, we'll then open up the call for Q&A.

Before we begin, we'd like to remind you that some of the statements made during the call today are forward-looking statements, including statements regarding expectations, timelines and clinical results for Arbutus' proprietary

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About ABUS

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ABUS

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.